Prestige Consumer Healthcare (PBH) 10-Q 3 Aug 23 2024 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Jun. 30, 2023	Jul. 28, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Entity File Number	001-32433
Entity Registrant Name	PRESTIGE CONSUMER HEALTHCARE INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-1297589
Entity Address, Address Line One	660 White Plains Road
Entity Address, City or Town	Tarrytown
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10591
City Area Code	914
Local Phone Number	524-6800
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	PBH
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		49,539,405
Entity Central Index Key	0001295947
Current Fiscal Year End Date	--03-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Revenues
Total revenues	$ 279,309	$ 277,059
Cost of Sales
Cost of sales excluding depreciation	122,654	114,996
Cost of sales depreciation	1,982	1,944
Cost of sales	124,636	116,940
Gross profit	154,673	160,119
Operating Expenses
Advertising and marketing	36,231	39,951
General and administrative	27,687	26,714
Depreciation and amortization	5,561	6,440
Total operating expenses	69,479	73,105
Operating income	85,194	87,014
Other expense
Interest expense, net	17,719	15,292
Other (income) expense, net	(1,238)	825
Total other expense, net	16,481	16,117
Income before income taxes	68,713	70,897
Provision for income taxes	15,437	15,625
Net income	$ 53,276	$ 55,272
Earnings per share:
Basic (in USD per share)	$ 1.07	$ 1.10
Diluted (in USD per share)	$ 1.06	$ 1.09
Weighted average shares outstanding:
Basic (in shares)	49,767	50,264
Diluted (in shares)	50,196	50,730
Comprehensive income, net of tax:
Currency translation adjustments	$ (646)	$ (9,519)
Net loss on termination of pension plan	0	(790)
Total other comprehensive loss	(646)	(10,309)
Comprehensive income	52,630	44,963
Net sales
Revenues
Total revenues	279,299	277,024
Other revenues
Revenues
Total revenues	$ 10	$ 35

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Mar. 31, 2023
Current assets
Cash and cash equivalents	$ 54,580	$ 58,489
Accounts receivable, net of allowance of $24,928 and $20,205, respectively	157,950	167,016
Inventories	169,849	162,121
Prepaid expenses and other current assets	9,379	4,117
Total current assets	391,758	391,743
Property, plant and equipment, net	69,979	70,412
Operating lease right-of-use assets	13,443	14,923
Finance lease right-of-use assets, net	3,535	4,200
Goodwill	527,458	527,553
Intangible assets, net	2,336,137	2,341,893
Other long-term assets	3,267	3,005
Total Assets	3,345,577	3,353,729
Current liabilities
Accounts payable	57,861	62,743
Accrued interest payable	15,188	15,688
Operating lease liabilities, current portion	6,600	6,926
Finance lease liabilities, current portion	2,855	2,834
Other accrued liabilities	64,767	72,524
Total current liabilities	147,271	160,715
Long-term debt, net	1,316,711	1,345,788
Deferred income tax liabilities	383,955	380,434
Long-term operating lease liabilities, net of current portion	8,217	9,876
Long-term finance lease liabilities, net of current portion	945	1,667
Other long-term liabilities	8,183	8,165
Total Liabilities	1,865,282	1,906,645
Commitments and Contingencies — Note 14
Stockholders' Equity
Preferred stock - $0.01 par value; Authorized - 5,000 shares; Issued and outstanding - None	0	0
Common stock - $0.01 par value; Authorized - 250,000 shares; Issued - 55,220 shares at June 30, 2023 and 54,857 shares at March 31, 2023	552	548
Additional paid-in capital	546,526	535,356
Treasury stock, at cost - 5,680 shares at June 30, 2023 and 5,165 shares at March 31, 2023	(219,707)	(189,114)
Accumulated other comprehensive loss, net of tax	(32,210)	(31,564)
Retained earnings	1,185,134	1,131,858
Total Stockholders' Equity	1,480,295	1,447,084
Total Liabilities and Stockholders' Equity	$ 3,345,577	$ 3,353,729

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2023	Mar. 31, 2023
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable, current	$ 24,928	$ 20,205
Stockholders' Equity:
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	55,220,000	54,857,000
Treasury stock (in shares)	5,680,000	5,165,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Other Comprehensive (Loss)	Retained Earnings
Common stock, beginning balance (in shares) at Mar. 31, 2022		54,430,000
Equity, beginning balance at Mar. 31, 2022	$ 1,577,611	$ 544	$ 515,583	$ (133,648)	$ (19,032)	$ 1,214,164
Treasury stock, beginning balance (in shares) at Mar. 31, 2022				4,151,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	$ 3,857		3,857
Exercise of stock options (in shares)	39,100	39,000
Exercise of stock options	$ 1,489	$ 1	1,488
Issuance of shares related to restricted stock (in shares)		221,000
Issuance of shares related to restricted stock	0	$ 2	(2)
Treasury share repurchases (in shares)				777,000
Treasury share repurchases	(43,177)			$ (43,177)
Net income	55,272					55,272
Comprehensive loss	(10,309)				(10,309)
Common stock, ending balance (in shares) at Jun. 30, 2022		54,690,000
Equity, ending balance at Jun. 30, 2022	1,584,743	$ 547	520,926	$ (176,825)	(29,341)	1,269,436
Treasury stock, ending balance (in shares) at Jun. 30, 2022				4,928,000
Common stock, beginning balance (in shares) at Mar. 31, 2023		54,857,000
Equity, beginning balance at Mar. 31, 2023	$ 1,447,084	$ 548	535,356	$ (189,114)	(31,564)	1,131,858
Treasury stock, beginning balance (in shares) at Mar. 31, 2023	5,165,000			5,165,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	$ 4,146		4,146
Exercise of stock options (in shares)	172,900	173,000
Exercise of stock options	$ 7,028	$ 2	7,026
Issuance of shares related to restricted stock (in shares)		190,000
Issuance of shares related to restricted stock	0	$ 2	(2)
Treasury share repurchases (in shares)				515,000
Treasury share repurchases	(30,593)			$ (30,593)
Net income	53,276					53,276
Comprehensive loss	(646)				(646)
Common stock, ending balance (in shares) at Jun. 30, 2023		55,220,000
Equity, ending balance at Jun. 30, 2023	$ 1,480,295	$ 552	$ 546,526	$ (219,707)	$ (32,210)	$ 1,185,134
Treasury stock, ending balance (in shares) at Jun. 30, 2023	5,680,000			5,680,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Operating Activities
Net income	$ 53,276	$ 55,272
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	7,543	8,384
Loss on disposal of property and equipment	0	13
Deferred income taxes	4,272	1,213
Amortization of debt origination costs	983	828
Stock-based compensation costs	4,146	3,857
Non-cash operating lease cost	1,244	1,493
Other	0	446
Changes in operating assets and liabilities:
Accounts receivable	5,632	(7,079)
Inventories	(7,711)	(14,415)
Prepaid expenses and other current assets	(5,181)	(3,227)
Accounts payable	(5,599)	2,542
Accrued liabilities	(8,519)	10,524
Operating lease liabilities	(1,745)	(1,602)
Other	(254)	(2)
Net cash provided by operating activities	48,087	58,247
Investing Activities
Purchases of property, plant and equipment	(1,477)	(1,047)
Other	3,800	0
Net cash provided by (used in) investing activities	2,323	(1,047)
Financing Activities
Term loan repayments	(30,000)	(15,000)
Borrowings under revolving credit agreement	0	20,000
Repayments under revolving credit agreement	0	(10,000)
Payments of finance leases	(699)	(686)
Proceeds from exercise of stock options	7,028	1,489
Fair value of shares surrendered as payment of tax withholding	(5,508)	(5,450)
Repurchase of common stock	(25,000)	(37,727)
Net cash used in financing activities	(54,179)	(47,374)
Effects of exchange rate changes on cash and cash equivalents	(140)	(1,142)
Increase (decrease) in cash and cash equivalents	(3,909)	8,684
Cash and cash equivalents - beginning of period	58,489	27,185
Cash and cash equivalents - end of period	54,580	35,869
Supplemental Cash Flow Information [Abstract]
Interest paid	17,582	3,562
Income taxes paid	$ 11,964	$ 1,799

Business and Basis of Presentat

Business and Basis of Presentation	3 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business and Basis of Presentation	Business and Basis of Presentation Nature of Business Prestige Consumer Healthcare Inc. (referred to herein as the “Company” or “we,” which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Consumer Healthcare Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (“OTC”) healthcare products to mass merchandisers, drug, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Prestige Consumer Healthcare Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 7 to these Condensed Consolidated Financial Statements. Economic Environment There has been economic uncertainty in the United States and globally due to several factors, including global supply chain constraints, rising interest rates, a high inflationary environment and geopolitical events. We expect economic conditions will continue to be highly volatile and uncertain, put pressure on prices and supply, and could affect demand for our products. We have continued to see changes in the purchasing patterns of our consumers, including a reduction in the frequency of visits to retailers and a shift in many markets to purchasing our products online. The volatile environment has impacted the supply of labor and raw materials and exacerbated rising input costs. Although we have not experienced a material disruption to our overall supply chain to date, we have and may continue to experience shortages, delays and backorders for certain ingredients and products, difficulty scheduling shipping for our products, as well as price increases from many of our suppliers for both shipping and product costs. In addition, labor shortages have impacted our manufacturing operations and may impact our ability to supply certain products to our customers. To date, these global conditions have not had a material negative impact on our operations, supply chain, overall costs or demand for most of our products or resulting aggregate sales and earnings, and, as such, it has also not materially negatively impacted our liquidity position. We continue to generate operating cash flows to meet our short-term liquidity needs. These circumstances could change, however, in this dynamic, unprecedented environment. If conditions cause further disruption in the global supply chain, the availability of labor and materials or otherwise further increase costs, it may materially affect our operations and those of third parties on which we rely, including causing material disruptions in the supply and distribution of our products. The extent to which these conditions impact our results and liquidity will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning global supply chain constraints, the high inflationary environment, global instability and the potential for further outbreaks of severe illnesses. These effects could have a material adverse impact on our business, liquidity, capital resources, and results of operations and those of the third parties on which we rely. Basis of Presentation The unaudited Condensed Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, these Condensed Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31st of each year. References in these Condensed Consolidated Financial Statements or related notes to a year (e.g., 2024) mean our fiscal year ending or ended on March 31st of that year. Operating results for the three months ended June 30, 2023 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2024. These unaudited Condensed Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. Our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and accounting for income taxes and related uncertain tax positions. Recently Adopted Accounting Pronouncements In October 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU requires entities to apply Topic 606 to recognize and measure contract assets and liabilities in a business combination. This ASU is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We adopted this standard effective April 1, 2023. The impact of the adoption of this new standard will depend on the magnitude of future acquisitions. Recently Issued Accounting Pronouncements In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting and also issued subsequent amendments to the initial guidance (collectively, "Topic 848"). In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848 , which extends the period of time preparers can utilize the reference rate reform relief guidance in Topic 848. Topic 848 provides optional guidance for contract modifications and certain hedging relationships associated with the transition from reference rates that are expected to be discontinued. On April 4, 2023, we entered into Amendment No. 8 ("ABL Amendment No. 8") to the 2012 ABL Revolver. ABL Amendment No. 8 provides for the replacement of LIBOR with Secured Overnight Financing Rate ("SOFR") as our reference rate. On June 12, 2023, we entered into Amendment No. 7 ("Term Loan Amendment No. 7") to the Company’s term loan originally entered into on January 31, 2012 (the “2012 Term Loan”), effective July 1, 2023. Term Loan Amendment No. 7 provides for the replacement of LIBOR with SOFR as our reference rate. Effective July 1, 2023, we have transitioned all discontinued reference rates to SOFR. The adoption of the standard did not have a material impact on our Consolidated Financial Statements.

Inventories

Inventories	3 Months Ended
	Jun. 30, 2023
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following: (In thousands) June 30, 2023 March 31, 2023 Components of Inventories Packaging and raw materials $ 22,671 $ 20,634 Work in process 291 220 Finished goods 146,887 141,267 Inventories $ 169,849 $ 162,121

Goodwill

Goodwill	3 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill A reconciliation of the activity affecting goodwill by operating segment is as follows: (In thousands) North American OTC International OTC Consolidated Balance - March 31, 2023 Goodwill $ 711,452 $ 30,204 $ 741,656 Accumulated impairment loss (212,516) (1,587) (214,103) Balance - March 31, 2023 498,936 28,617 527,553 Adjustment related to acquisition — — — Effects of foreign currency exchange rates — (95) (95) Balance - June 30, 2023 Goodwill 711,452 30,109 741,561 Accumulated impairment loss (212,516) (1,587) (214,103) Balance - June 30, 2023 $ 498,936 $ 28,522 $ 527,458 On an annual basis during the fourth quarter of each fiscal year, or more frequently if conditions indicate that the carrying value of the asset may not be recoverable, management performs a review of the values assigned to goodwill and tests for impairment. The date of our annual impairment review was February 28, 2023, and we recorded impairment charges to

Intangible Assets, net

Intangible Assets, net	3 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, net	Intangible Assets, net A reconciliation of the activity affecting intangible assets, net is as follows: (In thousands) Indefinite- Finite-Lived Totals Gross Carrying Amounts Balance — March 31, 2023 $ 2,168,902 $ 411,118 $ 2,580,020 Effects of foreign currency exchange rates (671) (145) (816) Balance — June 30, 2023 $ 2,168,231 $ 410,973 $ 2,579,204 Accumulated Amortization Balance — March 31, 2023 $ — $ 238,127 $ 238,127 Additions — 4,953 4,953 Effects of foreign currency exchange rates — (13) (13) Balance — June 30, 2023 $ — $ 243,067 $ 243,067 Intangible assets, net - June 30, 2023 $ 2,168,231 $ 167,906 $ 2,336,137 Amortization expense was $5.0 million and $5.6 million for the three months ended June 30, 2023 and 2022, respectively. Finite-lived intangible assets are expected to be amortized over their estimated useful life, which ranges from a period of 10 to 25 years, and the estimated amortization expense for each of the five succeeding years and the periods thereafter is as follows (in thousands): (In thousands) Year Ending March 31, Amount 2024 (remaining nine months ended March 31, 2024) $ 15,433 2025 18,906 2026 16,956 2027 15,363 2028 13,017 Thereafter 88,231 $ 167,906 Under accounting guidelines, indefinite-lived assets are not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below the carrying amount. The date of our annual impairment review was February 28, 2023, and we recorded impairment charges to intangible assets of $321.4 million in our March 31, 2023 financial statements. Additionally, at each reporting period, an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life. Intangible assets with finite lives are amortized over their respective estimated useful lives and are also tested for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value. We utilize the excess earnings method to estimate the fair value of our individual indefinite-lived intangible assets. The assumptions subject to significant uncertainties in the analysis include the discount rate utilized in the analysis, as well as future sales, gross margins, and advertising and marketing expenses. The discount rate assumption may be influenced by such factors as changes in interest rates and rates of inflation, which can have an impact on the determination of fair value. Additionally, should the related fair values of intangible assets be adversely affected as a result of declining sales or margins caused by competition, changing consumer needs or preferences, technological advances, changes in advertising and marketing expenses, or the potential impacts of supply chain constraints, labor shortages, or inflation, we may be required to record impairment charges in the future. As of June 30, 2023, no events have occurred that would indicate potential impairment of intangible assets.

Leases

Leases	3 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Leases	Leases We lease real estate and equipment for use in our operations. The components of lease expense for the three months ended June 30, 2023 and 2022 were as follows: Three Months Ended June 30, (In thousands) 2023 2022 Finance lease cost: Amortization of right-of-use assets $ 665 $ 665 Interest on lease liabilities 30 50 Operating lease cost 1,624 1,634 Short term lease cost 33 34 Variable lease cost 16,456 11,999 Total net lease cost $ 18,808 $ 14,382 As of June 30, 2023, the maturities of lease liabilities were as follows: (In thousands) Year Ending March 31, Operating Leases Finance Total 2024 (remaining nine months ending March 31, 2024) $ 5,265 $ 2,191 $ 7,456 2025 4,743 1,509 6,252 2026 2,260 96 2,356 2027 1,889 80 1,969 2028 1,436 — 1,436 Thereafter 264 — 264 Total undiscounted lease payments 15,857 3,876 19,733 Less amount of lease payments representing interest (1,040) (76) (1,116) Total present value of lease payments $ 14,817 $ 3,800 $ 18,617 The weighted average remaining lease term and weighted average discount rate were as follows: June 30, 2023 Weighted average remaining lease term (years) Operating leases 3.15 Finance leases 1.45 Weighted average discount rate Operating leases 3.51 % Finance leases 2.95 %
Leases	Leases We lease real estate and equipment for use in our operations. The components of lease expense for the three months ended June 30, 2023 and 2022 were as follows: Three Months Ended June 30, (In thousands) 2023 2022 Finance lease cost: Amortization of right-of-use assets $ 665 $ 665 Interest on lease liabilities 30 50 Operating lease cost 1,624 1,634 Short term lease cost 33 34 Variable lease cost 16,456 11,999 Total net lease cost $ 18,808 $ 14,382 As of June 30, 2023, the maturities of lease liabilities were as follows: (In thousands) Year Ending March 31, Operating Leases Finance Total 2024 (remaining nine months ending March 31, 2024) $ 5,265 $ 2,191 $ 7,456 2025 4,743 1,509 6,252 2026 2,260 96 2,356 2027 1,889 80 1,969 2028 1,436 — 1,436 Thereafter 264 — 264 Total undiscounted lease payments 15,857 3,876 19,733 Less amount of lease payments representing interest (1,040) (76) (1,116) Total present value of lease payments $ 14,817 $ 3,800 $ 18,617 The weighted average remaining lease term and weighted average discount rate were as follows: June 30, 2023 Weighted average remaining lease term (years) Operating leases 3.15 Finance leases 1.45 Weighted average discount rate Operating leases 3.51 % Finance leases 2.95 %

Other Accrued Liabilities

Other Accrued Liabilities	3 Months Ended
	Jun. 30, 2023
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other Accrued Liabilities Other accrued liabilities consist of the following: (In thousands) June 30, 2023 March 31, 2023 Accrued marketing costs $ 33,143 $ 30,471 Accrued compensation costs 5,807 14,292 Accrued broker commissions 1,958 1,767 Income taxes payable 9,764 10,645 Accrued professional fees 4,056 4,254 Accrued production costs 4,593 5,700 Other accrued liabilities 5,446 5,395 $ 64,767 $ 72,524

Long-Term Debt

Long-Term Debt	3 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt Long-term debt consists of the following, as of the dates indicated: (In thousands, except percentages) June 30, 2023 March 31, 2023 2021 Senior Notes bearing interest at 3.750%, with interest payable on April 1 and October 1 of each year. The 2021 Senior Notes mature on April 1, 2031. $ 600,000 $ 600,000 2019 Senior Notes bearing interest at 5.125%, with interest payable on January 15 and July 15 of each year. The 2019 Senior Notes mature on January 15, 2028. 400,000 400,000 2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.50%, or an alternate base rate plus a margin of 1.00% per annum, due on July 1, 2028. * 330,000 360,000 2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR (at March 31, 2023) and SOFR (at June 30, 2023) plus applicable margin. Any unpaid balance is due on December 11, 2024. — — Long-term debt 1,330,000 1,360,000 Less: unamortized debt costs (13,289) (14,212) Long-term debt, net $ 1,316,711 $ 1,345,788 * On June 12, 2023, we entered into Term Loan Amendment No. 7 to the Company’s 2012 Term Loan , effective July 1, 2023. Term Loan Amendment No. 7 provides for the replacement of LIBOR with SOFR as our reference rate. At June 30, 2023, we had no balance outstanding on the Company's asset-based revolving credit facility originally entered into on January 31, 2012 (the "2012 ABL Revolver") and a borrowing capacity of $174.9 million. On April 4, 2023, we entered into Amendment No. 8 to the 2012 ABL Revolver. ABL Amendment No. 8 provides for the replacement of LIBOR with SOFR as our reference rate. As of June 30, 2023, aggregate future principal payments required in accordance with the terms of the 2012 Term B-5 Loans under the 2012 Term Loan, the 2012 ABL Revolver and the indentures governing the senior unsecured notes due 2031 (the "2021 Senior Notes") and the senior unsecured notes due 2028 (the "2019 Senior Notes") are as follows: (In thousands) Year Ending March 31, Amount 2024 (remaining nine months ending March 31, 2024) $ — 2025 — 2026 — 2027 — 2028 400,000 Thereafter 930,000 $ 1,330,000

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts. FASB Accounting Standards Codification ("ASC") 820, Fair Value Measurements , requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. ASC 820 established market (observable inputs) as the preferred source of fair value, to be followed by our assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created: Level 1 - Quoted market prices for identical instruments in active markets; Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and Level 3 - Unobservable inputs developed by us using estimates and assumptions reflective of those that would be utilized by a market participant. The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the 2021 Senior Notes, the 2019 Senior Notes, the 2012 Term B-5 Loans, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy. The summary below details the carrying amounts and estimated fair values of these instruments at June 30, 2023 and March 31, 2023. June 30, 2023 March 31, 2023 (In thousands) Carrying Value Fair Value Carrying Value Fair Value 2019 Senior Notes 400,000 379,000 400,000 383,500 2021 Senior Notes 600,000 493,500 600,000 510,750 2012 Term B-5 Loans 330,000 329,175 360,000 359,550

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Jun. 30, 2023
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders' Equity We are authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share. The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof. Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of outstanding stock having priority rights as to dividends. No dividends have been declared or paid on our common stock through June 30, 2023. On May 2, 2023, the Company's Board of Directors authorized the repurchase of up to $25.0 million of the Company's issued and outstanding common stock through May 31, 2024 utilizing open market transactions, transactions structured through investment banking institutions, in privately-negotiated transactions, by direct purchases of common stock or a combination of the foregoing in compliance with the applicable rules and regulations of the Securities and Exchange Commission. We completed the repurchase in the first quarter of fiscal 2024. During the three months ended June 30, 2023 and 2022, we repurchased shares of our common stock and recorded them as treasury stock. Our share repurchases consisted of the following: Three Months Ended June 30, 2023 2022 Shares repurchased pursuant to the provisions of the various employee restricted stock awards: Number of shares 88,953 99,219 Average price per share $61.92 $54.94 Total amount repurchased $5.5 million $5.5 million Shares repurchased in conjunction with our share repurchase program: Number of shares 426,479 677,555 Average price per share $58.62 $55.68 Total amount repurchased $25.0 million $37.7 million

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	3 Months Ended
	Jun. 30, 2023
Stockholders' Equity Note [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss Accumulated other comprehensive loss consisted of the following at June 30, 2023 and March 31, 2023: (In thousands) June 30, 2023 March 31, 2023 Components of Accumulated Other Comprehensive Loss Cumulative translation adjustment $ (32,926) $ (32,280) Unrecognized net gain on pension plans, net of tax of $(214) and $(214), respectively 716 716 Accumulated other comprehensive loss, net of tax $ (32,210) $ (31,564)

Earnings Per Share

Earnings Per Share	3 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Basic earnings per share is computed based on income available to common stockholders and the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on income available to common stockholders and the weighted average number of shares of common stock outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method, which includes stock options, restricted stock units ("RSUs") and performance stock units ("PSUs"). Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options and unvested RSUs, are included in the diluted earnings per share calculation to the extent that they are dilutive. In loss periods, the assumed exercise of in-the-money stock options and RSUs has an anti-dilutive effect, and therefore these instruments are excluded from the computation of diluted earnings per share. The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended June 30, (In thousands, except per share data) 2023 2022 Numerator Net income $ 53,276 $ 55,272 Denominator Denominator for basic earnings per share — weighted average shares outstanding 49,767 50,264 Dilutive effect of unvested restricted stock units and options issued to employees and directors 429 466 Denominator for diluted earnings per share 50,196 50,730 Earnings per Common Share: Basic earnings per share $ 1.07 $ 1.10 Diluted earnings per share $ 1.06 $ 1.09

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “2005 Plan”), which provided for grants of up to a maximum of 5.0 million shares of restricted stock, stock options, RSUs and other equity-based awards. In June 2014, the Board of Directors approved, and in July 2014, our stockholders ratified, an increase of an additional 1.8 million shares of our common stock for issuance under the 2005 Plan, among other changes. On June 23, 2020, the Board of Directors adopted the Prestige Consumer Healthcare Inc. 2020 Long-Term Incentive Plan (the “2020 Plan”). The 2020 Plan became effective on August 4, 2020, upon the approval of the 2020 Plan by our stockholders. On June 23, 2020, a total of 2,827,210 shares were available for issuance under the 2020 Plan (comprised of 2,000,000 new shares plus 827,210 shares that were unissued under the 2005 Plan). All future equity awards will be made from the 2020 Plan, and the Company will not grant any additional awards under the 2005 Plan. The following table provides information regarding our stock-based compensation: Three Months Ended June 30, (In thousands) 2023 2022 Pre-tax stock-based compensation costs charged against income $ 4,146 $ 3,857 Income tax benefit recognized on compensation costs $ 406 $ 537 Total fair value of options and RSUs vested during the period $ 11,226 $ 10,225 Cash received from the exercise of stock options $ 7,028 $ 1,489 Tax benefits realized from tax deductions resulting from RSU issuances and stock option exercises $ 876 $ 2,895 At June 30, 2023, there were $4.6 million of unrecognized compensation costs related to unvested stock options under the 2005 Plan and the 2020 Plan, excluding an estimate for forfeitures which may occur. We expect to recognize such costs over a weighted average period of 2.3 years. At June 30, 2023, there were $15.1 million of unrecognized compensation costs related to unvested RSUs and PSUs under the 2005 Plan and the 2020 Plan, excluding an estimate for forfeitures which may occur. We expect to recognize such costs over a weighted average period of 2.3 years. At June 30, 2023, there were 1.9 million shares available for issuance under the 2020 Plan. Restricted Stock Units The fair value of the RSUs is determined using the closing price of our common stock on the date of the grant. A summary of the RSUs granted under the 2005 Plan and the 2020 Plan is presented below: RSUs Shares (in thousands) Weighted Three Months Ended June 30, 2022 Unvested at March 31, 2022 440.9 $ 38.45 Granted 134.0 54.47 Incremental performance shares 42.4 — Vested (222.4) 32.05 Unvested at June 30, 2022 394.9 46.65 Vested at June 30, 2022 108.5 36.54 Three Months Ended June 30, 2023 Unvested at March 31, 2023 409.0 $ 47.17 Granted 142.8 61.73 Incremental performance shares 41.3 — Vested (189.3) 41.81 Forfeited (4.2) 54.92 Unvested at June 30, 2023 399.6 54.18 Vested at June 30, 2023 108.5 36.54 Options The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions presented below: Three Months Ended June 30, 2023 2022 Expected volatility 30.2% - 31.6% 30.8% - 30.9% Expected dividends $ — $ — Expected term in years 6.0 to 7.0 6.0 to 7.0 Risk-free rate 3.6% 2.8% to 2.9% Weighted average grant date fair value of options granted $ 23.75 $ 20.10 A summary of option activity under the 2005 Plan and the 2020 Plan is as follows: Options Shares (in thousands) Weighted Weighted Aggregate Three Months Ended June 30, 2022 Outstanding at March 31, 2022 1,100.9 $ 40.62 Granted 197.6 54.48 Exercised (39.1) 38.04 Outstanding at June 30, 2022 1,259.4 42.88 6.9 $ 20,052 Vested at June 30, 2022 827.0 39.98 5.7 $ 15,567 Three Months Ended June 30, 2023 Outstanding at March 31, 2023 1,081.0 $ 43.96 Granted 128.1 61.73 Exercised (172.9) 40.64 Forfeited (19.3) 54.86 Expired (1.7) 54.47 Outstanding at June 30, 2023 1,015.2 46.54 6.5 $ 13,369 Vested at June 30, 2023 700.1 42.70 5.4 $ 11,714 The aggregate intrinsic value of options exercised during the three months ended June 30, 2023 was $3.2 million.

Income Taxes

Income Taxes	3 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesIncome taxes are recorded in our quarterly financial statements based on our estimated annual effective income tax rate, subject to adjustments for discrete events, should they occur. The effective tax rates used in the calculation of income taxes were 22.5% and 22.0% for the three months ended June 30, 2023 and 2022, respectively. The increase in the effective tax rate for the three months ended June 30, 2023, compared to the three months ended June 30, 2022, was due to discrete items primarily pertaining to state tax rate legislative changes and stock-based compensation.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and ContingenciesWe are involved from time to time in legal matters and other claims incidental to our business.  We review outstanding claims and proceedings internally and with external counsel as necessary to assess the probability and amount of a potential loss.  These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted.  The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve.  In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement).  We believe the reasonably possible losses from resolution of routine legal matters and other claims incidental to our business, taking our reserves into account, will not have a material adverse effect on our business, financial condition, or results of operations.

Concentrations of Risk

Concentrations of Risk	3 Months Ended
	Jun. 30, 2023
Risks and Uncertainties [Abstract]
Concentrations of Risk	Concentrations of Risk Our revenues are concentrated in the area of OTC Healthcare. We sell our products to mass merchandisers, drug, food, dollar, convenience and club stores and e-commerce channels. During the three months ended June 30, 2023 and 2022, approximately 41.0% and 41.5%, respectively, of our gross revenues were derived from our five top selling brands. Walmart accounted for approximately 20.8% and 19.9%, respectively, of our gross revenues for the three months ended June 30, 2023 and 2022. An additional customer, Amazon, accounted for 11.0% of our gross revenues for the first quarter of the current fiscal year. Our product distribution in the United States is managed by a third party through one primary distribution center in Clayton, Indiana. In addition, we operate one manufacturing facility for certain of our products located in Lynchburg, Virginia, which manufactures many of the Summer's Eve and Fleet products. A natural disaster, such as tornado, earthquake, flood, or fire, could damage our inventory and/or materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. In addition, a serious disruption caused by performance or contractual issues with our third-party distribution manager or labor shortages or public health emergencies at our distribution center or manufacturing facility could materially impact our product distribution. Any disruption could result in increased costs, expense and/or shipping times, and could cause us to incur customer fees and penalties. We could also incur significantly higher costs and experience longer lead times if we need to replace our distribution center, the third-party distribution manager or the manufacturing facility. As a result, any serious disruption could have a material adverse effect on our business, financial condition and results of operations. At June 30, 2023, we had relationships with 135 third-party manufacturers. Of those, we had long-term contracts with 27 manufacturers that produced items that accounted for approximately 74.8% of gross sales for the three months ended June 30, 2023. At June 30, 2022, we had relationships with 129 third-party manufacturers. Of those, we had long-term contracts with 25 manufacturers that produced items that accounted for approximately 71.0% of gross sales for the three months ended June 30, 2022. The fact that we do not have long-term contracts with certain manufacturers means that they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business and results of operations. Although we are continually in the process of negotiating long-term contracts with certain key manufacturers, we may not be able to reach a timely agreement, which could have a material adverse effect on our business and results of operations.

Business Segments

Business Segments	3 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Business Segments	Business Segments Segment information has been prepared in accordance with the Segment Reporting topic of the FASB ASC 280. Our current reportable segments consist of (i) North American OTC Healthcare and (ii) International OTC Healthcare. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and marketing expenses. The tables below summarize information about our reportable segments. Three Months Ended June 30, 2023 (In thousands) North American OTC International OTC Consolidated Total segment revenues* $ 246,143 $ 33,166 $ 279,309 Cost of sales 110,076 14,560 124,636 Gross profit 136,067 18,606 154,673 Advertising and marketing 31,401 4,830 36,231 Contribution margin $ 104,666 $ 13,776 118,442 Other operating expenses 33,248 Operating income $ 85,194 * Intersegment revenues of $1.4 million were eliminated from the North American OTC Healthcare segment. Three Months Ended June 30, 2022 (In thousands) North American OTC International OTC Consolidated Total segment revenues* $ 242,518 $ 34,541 $ 277,059 Cost of sales 102,921 14,019 116,940 Gross profit 139,597 20,522 160,119 Advertising and marketing 35,412 4,539 39,951 Contribution margin $ 104,185 $ 15,983 120,168 Other operating expenses 33,154 Operating income $ 87,014 * Intersegment revenues of $0.5 million were eliminated from the North American OTC Healthcare segment. The tables below summarize information about our segment revenues from similar product groups. Three Months Ended June 30, 2023 (In thousands) North American OTC International OTC Consolidated Analgesics $ 27,182 $ 842 $ 28,024 Cough & Cold 20,374 6,052 26,426 Women's Health 54,955 4,956 59,911 Gastrointestinal 44,681 12,910 57,591 Eye & Ear Care 39,471 4,021 43,492 Dermatologicals 34,678 1,338 36,016 Oral Care 21,726 3,022 24,748 Other OTC 3,076 25 3,101 Total segment revenues $ 246,143 $ 33,166 $ 279,309 Three Months Ended June 30, 2022 (In thousands) North American OTC International OTC Consolidated Analgesics $ 27,797 $ 453 $ 28,250 Cough & Cold 21,592 6,271 27,863 Women's Health 61,184 4,867 66,051 Gastrointestinal 40,067 14,027 54,094 Eye & Ear Care 38,611 4,736 43,347 Dermatologicals 29,455 1,006 30,461 Oral Care 20,975 3,170 24,145 Other OTC 2,837 11 2,848 Total segment revenues $ 242,518 $ 34,541 $ 277,059

Subsequent Event

Subsequent Event	3 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event Director Equity Grants Pursuant to the 2020 Plan, each of the independent members of the Board of Directors received a grant of 2,295 RSUs on August 1, 2023. The RSUs fully vest one year after receipt of the award, subject to the continued service of the director on such vesting date, and will be settled by delivery to each director of one share of our common stock for each vested RSU either (a) at the election of the director prior to the grant date, immediately upon vesting, or (b) promptly following the earliest of (i) such director's death, (ii) such director's separation from service or (iii) a change in control of the Company.

Business and Basis of Present_2

Business and Basis of Presentation (Policies)	3 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The unaudited Condensed Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, these Condensed Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31st of each year. References in these Condensed Consolidated Financial Statements or related notes to a year (e.g., 2024) mean our fiscal year ending or ended on March 31st of that year. Operating results for the three months ended June 30, 2023 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2024. These unaudited Condensed Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023.
Use of Estimates	Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.  Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. Our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and accounting for income taxes and related uncertain tax positions.
Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements	Recently Adopted Accounting Pronouncements In October 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU requires entities to apply Topic 606 to recognize and measure contract assets and liabilities in a business combination. This ASU is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We adopted this standard effective April 1, 2023. The impact of the adoption of this new standard will depend on the magnitude of future acquisitions. Recently Issued Accounting Pronouncements In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting and also issued subsequent amendments to the initial guidance (collectively, "Topic 848"). In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848 , which extends the period of time preparers can utilize the reference rate reform relief guidance in Topic 848. Topic 848 provides optional guidance for contract modifications and certain hedging relationships associated with the transition from reference rates that are expected to be discontinued. On April 4, 2023, we entered into Amendment No. 8 ("ABL Amendment No. 8") to the 2012 ABL Revolver. ABL Amendment No. 8 provides for the replacement of LIBOR with Secured Overnight Financing Rate ("SOFR") as our reference rate. On June 12, 2023, we entered into Amendment No. 7 ("Term Loan Amendment No. 7") to the Company’s term loan originally entered into on January 31, 2012 (the “2012 Term Loan”), effective July 1, 2023. Term Loan Amendment No. 7 provides for the replacement of LIBOR with SOFR as our reference rate. Effective July 1, 2023, we have transitioned all discontinued reference rates to SOFR. The adoption of the standard did not have a material impact on our Consolidated Financial Statements.

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Jun. 30, 2023
Inventory Disclosure [Abstract]
Inventories	Inventories consist of the following: (In thousands) June 30, 2023 March 31, 2023 Components of Inventories Packaging and raw materials $ 22,671 $ 20,634 Work in process 291 220 Finished goods 146,887 141,267 Inventories $ 169,849 $ 162,121

Goodwill (Tables)

Goodwill (Tables)	3 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Reconciliation of the Activity Affecting Goodwill	A reconciliation of the activity affecting goodwill by operating segment is as follows: (In thousands) North American OTC International OTC Consolidated Balance - March 31, 2023 Goodwill $ 711,452 $ 30,204 $ 741,656 Accumulated impairment loss (212,516) (1,587) (214,103) Balance - March 31, 2023 498,936 28,617 527,553 Adjustment related to acquisition — — — Effects of foreign currency exchange rates — (95) (95) Balance - June 30, 2023 Goodwill 711,452 30,109 741,561 Accumulated impairment loss (212,516) (1,587) (214,103) Balance - June 30, 2023 $ 498,936 $ 28,522 $ 527,458

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	3 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Reconciliation of the Activity Affecting Finite Lived Intangible Assets	A reconciliation of the activity affecting intangible assets, net is as follows: (In thousands) Indefinite- Finite-Lived Totals Gross Carrying Amounts Balance — March 31, 2023 $ 2,168,902 $ 411,118 $ 2,580,020 Effects of foreign currency exchange rates (671) (145) (816) Balance — June 30, 2023 $ 2,168,231 $ 410,973 $ 2,579,204 Accumulated Amortization Balance — March 31, 2023 $ — $ 238,127 $ 238,127 Additions — 4,953 4,953 Effects of foreign currency exchange rates — (13) (13) Balance — June 30, 2023 $ — $ 243,067 $ 243,067 Intangible assets, net - June 30, 2023 $ 2,168,231 $ 167,906 $ 2,336,137
Reconciliation of the Activity Affecting Indefinite Lived Intangible Assets	A reconciliation of the activity affecting intangible assets, net is as follows: (In thousands) Indefinite- Finite-Lived Totals Gross Carrying Amounts Balance — March 31, 2023 $ 2,168,902 $ 411,118 $ 2,580,020 Effects of foreign currency exchange rates (671) (145) (816) Balance — June 30, 2023 $ 2,168,231 $ 410,973 $ 2,579,204 Accumulated Amortization Balance — March 31, 2023 $ — $ 238,127 $ 238,127 Additions — 4,953 4,953 Effects of foreign currency exchange rates — (13) (13) Balance — June 30, 2023 $ — $ 243,067 $ 243,067 Intangible assets, net - June 30, 2023 $ 2,168,231 $ 167,906 $ 2,336,137
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Finite-lived intangible assets are expected to be amortized over their estimated useful life, which ranges from a period of 10 to 25 years, and the estimated amortization expense for each of the five succeeding years and the periods thereafter is as follows (in thousands): (In thousands) Year Ending March 31, Amount 2024 (remaining nine months ended March 31, 2024) $ 15,433 2025 18,906 2026 16,956 2027 15,363 2028 13,017 Thereafter 88,231 $ 167,906

Leases (Tables)

Leases (Tables)	3 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Components of Lease Expense	The components of lease expense for the three months ended June 30, 2023 and 2022 were as follows: Three Months Ended June 30, (In thousands) 2023 2022 Finance lease cost: Amortization of right-of-use assets $ 665 $ 665 Interest on lease liabilities 30 50 Operating lease cost 1,624 1,634 Short term lease cost 33 34 Variable lease cost 16,456 11,999 Total net lease cost $ 18,808 $ 14,382 The weighted average remaining lease term and weighted average discount rate were as follows: June 30, 2023 Weighted average remaining lease term (years) Operating leases 3.15 Finance leases 1.45 Weighted average discount rate Operating leases 3.51 % Finance leases 2.95 %
Maturities of Operating Leases	As of June 30, 2023, the maturities of lease liabilities were as follows: (In thousands) Year Ending March 31, Operating Leases Finance Total 2024 (remaining nine months ending March 31, 2024) $ 5,265 $ 2,191 $ 7,456 2025 4,743 1,509 6,252 2026 2,260 96 2,356 2027 1,889 80 1,969 2028 1,436 — 1,436 Thereafter 264 — 264 Total undiscounted lease payments 15,857 3,876 19,733 Less amount of lease payments representing interest (1,040) (76) (1,116) Total present value of lease payments $ 14,817 $ 3,800 $ 18,617
Maturities of Finance Leases	As of June 30, 2023, the maturities of lease liabilities were as follows: (In thousands) Year Ending March 31, Operating Leases Finance Total 2024 (remaining nine months ending March 31, 2024) $ 5,265 $ 2,191 $ 7,456 2025 4,743 1,509 6,252 2026 2,260 96 2,356 2027 1,889 80 1,969 2028 1,436 — 1,436 Thereafter 264 — 264 Total undiscounted lease payments 15,857 3,876 19,733 Less amount of lease payments representing interest (1,040) (76) (1,116) Total present value of lease payments $ 14,817 $ 3,800 $ 18,617

Other Accrued Liabilities (Tabl

Other Accrued Liabilities (Tables)	3 Months Ended
	Jun. 30, 2023
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other accrued liabilities consist of the following: (In thousands) June 30, 2023 March 31, 2023 Accrued marketing costs $ 33,143 $ 30,471 Accrued compensation costs 5,807 14,292 Accrued broker commissions 1,958 1,767 Income taxes payable 9,764 10,645 Accrued professional fees 4,056 4,254 Accrued production costs 4,593 5,700 Other accrued liabilities 5,446 5,395 $ 64,767 $ 72,524

Long-Term Debt (Tables)

Long-Term Debt (Tables)	3 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Long-term debt consists of the following, as of the dates indicated: (In thousands, except percentages) June 30, 2023 March 31, 2023 2021 Senior Notes bearing interest at 3.750%, with interest payable on April 1 and October 1 of each year. The 2021 Senior Notes mature on April 1, 2031. $ 600,000 $ 600,000 2019 Senior Notes bearing interest at 5.125%, with interest payable on January 15 and July 15 of each year. The 2019 Senior Notes mature on January 15, 2028. 400,000 400,000 2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.50%, or an alternate base rate plus a margin of 1.00% per annum, due on July 1, 2028. * 330,000 360,000 2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR (at March 31, 2023) and SOFR (at June 30, 2023) plus applicable margin. Any unpaid balance is due on December 11, 2024. — — Long-term debt 1,330,000 1,360,000 Less: unamortized debt costs (13,289) (14,212) Long-term debt, net $ 1,316,711 $ 1,345,788 * On June 12, 2023, we entered into Term Loan Amendment No. 7 to the Company’s 2012 Term Loan , effective July 1, 2023. Term Loan Amendment No. 7 provides for the replacement of LIBOR with SOFR as our reference rate.
Aggregate Future Principal Payments	As of June 30, 2023, aggregate future principal payments required in accordance with the terms of the 2012 Term B-5 Loans under the 2012 Term Loan, the 2012 ABL Revolver and the indentures governing the senior unsecured notes due 2031 (the "2021 Senior Notes") and the senior unsecured notes due 2028 (the "2019 Senior Notes") are as follows: (In thousands) Year Ending March 31, Amount 2024 (remaining nine months ending March 31, 2024) $ — 2025 — 2026 — 2027 — 2028 400,000 Thereafter 930,000 $ 1,330,000

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Summary of Carry Amounts and Fair Value Measurements	The summary below details the carrying amounts and estimated fair values of these instruments at June 30, 2023 and March 31, 2023. June 30, 2023 March 31, 2023 (In thousands) Carrying Value Fair Value Carrying Value Fair Value 2019 Senior Notes 400,000 379,000 400,000 383,500 2021 Senior Notes 600,000 493,500 600,000 510,750 2012 Term B-5 Loans 330,000 329,175 360,000 359,550

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Jun. 30, 2023
Stockholders' Equity Note [Abstract]
Class of Treasury Stock	Our share repurchases consisted of the following: Three Months Ended June 30, 2023 2022 Shares repurchased pursuant to the provisions of the various employee restricted stock awards: Number of shares 88,953 99,219 Average price per share $61.92 $54.94 Total amount repurchased $5.5 million $5.5 million Shares repurchased in conjunction with our share repurchase program: Number of shares 426,479 677,555 Average price per share $58.62 $55.68 Total amount repurchased $25.0 million $37.7 million

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	3 Months Ended
	Jun. 30, 2023
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Loss	Accumulated other comprehensive loss consisted of the following at June 30, 2023 and March 31, 2023: (In thousands) June 30, 2023 March 31, 2023 Components of Accumulated Other Comprehensive Loss Cumulative translation adjustment $ (32,926) $ (32,280) Unrecognized net gain on pension plans, net of tax of $(214) and $(214), respectively 716 716 Accumulated other comprehensive loss, net of tax $ (32,210) $ (31,564)

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended June 30, (In thousands, except per share data) 2023 2022 Numerator Net income $ 53,276 $ 55,272 Denominator Denominator for basic earnings per share — weighted average shares outstanding 49,767 50,264 Dilutive effect of unvested restricted stock units and options issued to employees and directors 429 466 Denominator for diluted earnings per share 50,196 50,730 Earnings per Common Share: Basic earnings per share $ 1.07 $ 1.10 Diluted earnings per share $ 1.06 $ 1.09

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Compensation Expense Information	The following table provides information regarding our stock-based compensation: Three Months Ended June 30, (In thousands) 2023 2022 Pre-tax stock-based compensation costs charged against income $ 4,146 $ 3,857 Income tax benefit recognized on compensation costs $ 406 $ 537 Total fair value of options and RSUs vested during the period $ 11,226 $ 10,225 Cash received from the exercise of stock options $ 7,028 $ 1,489 Tax benefits realized from tax deductions resulting from RSU issuances and stock option exercises $ 876 $ 2,895
Summary of Restricted Shares	A summary of the RSUs granted under the 2005 Plan and the 2020 Plan is presented below: RSUs Shares (in thousands) Weighted Three Months Ended June 30, 2022 Unvested at March 31, 2022 440.9 $ 38.45 Granted 134.0 54.47 Incremental performance shares 42.4 — Vested (222.4) 32.05 Unvested at June 30, 2022 394.9 46.65 Vested at June 30, 2022 108.5 36.54 Three Months Ended June 30, 2023 Unvested at March 31, 2023 409.0 $ 47.17 Granted 142.8 61.73 Incremental performance shares 41.3 — Vested (189.3) 41.81 Forfeited (4.2) 54.92 Unvested at June 30, 2023 399.6 54.18 Vested at June 30, 2023 108.5 36.54
Fair Value of Options Granted	The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions presented below: Three Months Ended June 30, 2023 2022 Expected volatility 30.2% - 31.6% 30.8% - 30.9% Expected dividends $ — $ — Expected term in years 6.0 to 7.0 6.0 to 7.0 Risk-free rate 3.6% 2.8% to 2.9% Weighted average grant date fair value of options granted $ 23.75 $ 20.10
Stock Option Activity	A summary of option activity under the 2005 Plan and the 2020 Plan is as follows: Options Shares (in thousands) Weighted Weighted Aggregate Three Months Ended June 30, 2022 Outstanding at March 31, 2022 1,100.9 $ 40.62 Granted 197.6 54.48 Exercised (39.1) 38.04 Outstanding at June 30, 2022 1,259.4 42.88 6.9 $ 20,052 Vested at June 30, 2022 827.0 39.98 5.7 $ 15,567 Three Months Ended June 30, 2023 Outstanding at March 31, 2023 1,081.0 $ 43.96 Granted 128.1 61.73 Exercised (172.9) 40.64 Forfeited (19.3) 54.86 Expired (1.7) 54.47 Outstanding at June 30, 2023 1,015.2 46.54 6.5 $ 13,369 Vested at June 30, 2023 700.1 42.70 5.4 $ 11,714

Business Segments (Tables)

Business Segments (Tables)	3 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Operating and Reportable Segments	The tables below summarize information about our reportable segments. Three Months Ended June 30, 2023 (In thousands) North American OTC International OTC Consolidated Total segment revenues* $ 246,143 $ 33,166 $ 279,309 Cost of sales 110,076 14,560 124,636 Gross profit 136,067 18,606 154,673 Advertising and marketing 31,401 4,830 36,231 Contribution margin $ 104,666 $ 13,776 118,442 Other operating expenses 33,248 Operating income $ 85,194 * Intersegment revenues of $1.4 million were eliminated from the North American OTC Healthcare segment. Three Months Ended June 30, 2022 (In thousands) North American OTC International OTC Consolidated Total segment revenues* $ 242,518 $ 34,541 $ 277,059 Cost of sales 102,921 14,019 116,940 Gross profit 139,597 20,522 160,119 Advertising and marketing 35,412 4,539 39,951 Contribution margin $ 104,185 $ 15,983 120,168 Other operating expenses 33,154 Operating income $ 87,014 * Intersegment revenues of $0.5 million were eliminated from the North American OTC Healthcare segment.
Revenues from Similar Product Groups	The tables below summarize information about our segment revenues from similar product groups. Three Months Ended June 30, 2023 (In thousands) North American OTC International OTC Consolidated Analgesics $ 27,182 $ 842 $ 28,024 Cough & Cold 20,374 6,052 26,426 Women's Health 54,955 4,956 59,911 Gastrointestinal 44,681 12,910 57,591 Eye & Ear Care 39,471 4,021 43,492 Dermatologicals 34,678 1,338 36,016 Oral Care 21,726 3,022 24,748 Other OTC 3,076 25 3,101 Total segment revenues $ 246,143 $ 33,166 $ 279,309 Three Months Ended June 30, 2022 (In thousands) North American OTC International OTC Consolidated Analgesics $ 27,797 $ 453 $ 28,250 Cough & Cold 21,592 6,271 27,863 Women's Health 61,184 4,867 66,051 Gastrointestinal 40,067 14,027 54,094 Eye & Ear Care 38,611 4,736 43,347 Dermatologicals 29,455 1,006 30,461 Oral Care 20,975 3,170 24,145 Other OTC 2,837 11 2,848 Total segment revenues $ 242,518 $ 34,541 $ 277,059

Inventories - Summary of Invent

Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Mar. 31, 2023
Inventory Disclosure [Abstract]
Packaging and raw materials	$ 22,671	$ 20,634
Work in process	291	220
Finished goods	146,887	141,267
Inventories	$ 169,849	$ 162,121

Inventories - Narrative (Detail

Inventories - Narrative (Details) - USD ($) $ in Millions	Jun. 30, 2023	Mar. 31, 2023
Inventory Disclosure [Abstract]
Inventory valuation reserves related to obsolete and slow-moving inventory	$ 4.9	$ 5.8

Goodwill - Schedule of Changes

Goodwill - Schedule of Changes (Details) $ in Thousands	3 Months Ended
	Jun. 30, 2023 USD ($)
Goodwill [Roll Forward]
Goodwill	$ 741,656
Accumulated impairment loss, beginning	(214,103)
Goodwill, net	527,553
Adjustment related to acquisition	0
Effects of foreign currency exchange rates	(95)
Goodwill, gross, ending	741,561
Accumulated impairment loss, ending	(214,103)
Goodwill, net, ending	527,458
North American OTC Healthcare
Goodwill [Roll Forward]
Goodwill	711,452
Accumulated impairment loss, beginning	(212,516)
Goodwill, net	498,936
Adjustment related to acquisition	0
Effects of foreign currency exchange rates	0
Goodwill, gross, ending	711,452
Accumulated impairment loss, ending	(212,516)
Goodwill, net, ending	498,936
International OTC Healthcare
Goodwill [Roll Forward]
Goodwill	30,204
Accumulated impairment loss, beginning	(1,587)
Goodwill, net	28,617
Adjustment related to acquisition	0
Effects of foreign currency exchange rates	(95)
Goodwill, gross, ending	30,109
Accumulated impairment loss, ending	(1,587)
Goodwill, net, ending	$ 28,522

Goodwill - Narrative (Details)

Goodwill - Narrative (Details) $ in Millions	12 Months Ended
	Mar. 31, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill, impairment loss	$ 48.8

Intangible Assets, net - Activi

Intangible Assets, net - Activity Affecting Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Mar. 31, 2023
Intangible Assets, Gross [Abstract]
Totals, gross, beginning balance	$ 2,580,020
Totals, effects of foreign currency exchange rate	(816)
Totals, gross, ending balance	2,579,204
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Accumulated amortization, beginning balance	238,127
Accumulated amortization, additions	4,953	$ 5,600
Accumulated amortization, effects of foreign exchange rates	(13)
Accumulated amortization, ending balance	243,067
Finite-Lived Intangible Assets, Net [Abstract]
Finite-Lived Intangible Assets, Net	167,906
Intangible Assets, Net [Abstract]
Intangible Assets, Net (Excluding Goodwill), Total	2,336,137		$ 2,341,893
Finite-Lived Trademarks and Customer Relationships
Finite-Lived Intangible Assets, Gross [Abstract]
Finite-lived trademarks and customer relationships, beginning balance	411,118
Finite-lived trademarks and customer relationships, effects of foreign currency exchange rate	(145)
Finite-lived trademarks and customer relationships, ending balance	410,973
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Accumulated amortization, beginning balance	238,127
Accumulated amortization, additions	4,953
Accumulated amortization, effects of foreign exchange rates	(13)
Accumulated amortization, ending balance	243,067
Finite-Lived Intangible Assets, Net [Abstract]
Finite-Lived Intangible Assets, Net	167,906
Indefinite- Lived Trademarks
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived trademarks, beginning balance	2,168,902
Indefinite lived trademarks, effects of foreign currency exchange rate	(671)
Indefinite-lived trademarks, ending balance	$ 2,168,231

Intangible Assets, net - Narrat

Intangible Assets, net - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Mar. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 4,953	$ 5,600
Impairment of intangible assets			$ 321,400
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	10 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	25 years

Intangible Assets, net - Future

Intangible Assets, net - Future Amortization of Intangible Assets (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2024 (remaining nine months ended March 31, 2024)	$ 15,433
2025	18,906
2026	16,956
2027	15,363
2028	13,017
Thereafter	88,231
Finite-lived intangible assets, net	$ 167,906

Leases - Lease Cost (Details)

Leases - Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Leases [Abstract]
Amortization of right-of-use assets	$ 665	$ 665
Interest on lease liabilities	30	50
Operating lease cost	1,624	1,634
Short term lease cost	33	34
Variable lease cost	16,456	11,999
Total net lease cost	$ 18,808	$ 14,382

Leases - Lease Maturities (Deta

Leases - Lease Maturities (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Operating Leases
2024 (remaining nine months ending March 31, 2024)	$ 5,265
2025	4,743
2026	2,260
2027	1,889
2028	1,436
Thereafter	264
Total undiscounted lease payments	15,857
Less amount of lease payments representing interest	(1,040)
Total present value of lease payments	14,817
Finance Lease
2024 (remaining nine months ending March 31, 2024)	2,191
2025	1,509
2026	96
2027	80
2028	0
Thereafter	0
Total undiscounted lease payments	3,876
Less amount of lease payments representing interest	(76)
Total present value of lease payments	3,800
Total
2024 (remaining nine months ending March 31, 2024)	7,456
2025	6,252
2026	2,356
2027	1,969
2028	1,436
Thereafter	264
Total undiscounted lease payments	19,733
Less amount of lease payments representing interest	(1,116)
Total present value of lease payments	$ 18,617

Leases - Additional Information

Leases - Additional Information (Details)	Jun. 30, 2023
Weighted average remaining lease term (years)
Operating leases	3 years 1 month 24 days
Finance leases	1 year 5 months 12 days
Weighted average discount rate
Operating leases	3.51%
Finance leases	2.95%

Other Accrued Liabilities (Deta

Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Mar. 31, 2023
Payables and Accruals [Abstract]
Accrued marketing costs	$ 33,143	$ 30,471
Accrued compensation costs	5,807	14,292
Accrued broker commissions	1,958	1,767
Income taxes payable	9,764	10,645
Accrued professional fees	4,056	4,254
Accrued production costs	4,593	5,700
Other accrued liabilities	5,446	5,395
Total other accrued liabilities	$ 64,767	$ 72,524

Long-Term Debt - Schedule of Lo

Long-Term Debt - Schedule of Long-term Debt (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Mar. 31, 2023
Debt Instrument [Line Items]
Total long-term debt (including current portion)	$ 1,330,000
Long-term debt, net	1,330,000	$ 1,360,000
Less: unamortized debt costs	(13,289)	(14,212)
Long-term debt, net	$ 1,316,711	1,345,788
Senior Notes | 2021 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate	3.75%
Total long-term debt (including current portion)	$ 600,000	600,000
Senior Notes | 2019 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate	5.125%
Total long-term debt (including current portion)	$ 400,000	400,000
Term Loans | 2012 Term B-5 Loans
Debt Instrument [Line Items]
Total long-term debt (including current portion)	$ 330,000	360,000
Term Loans | 2012 Term B-5 Loans | LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	2%
Debt instrument, variable rate, minimum	0.50%
Term Loans | 2012 Term B-5 Loans | Base Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	1%
Revolving Credit Facility | 2012 ABL Revolver
Debt Instrument [Line Items]
Total long-term debt (including current portion)	$ 0	$ 0

Long-Term Debt - Narrative (Det

Long-Term Debt - Narrative (Details)	Jun. 30, 2023 USD ($)
Debt Instrument [Line Items]
Long-term debt outstanding	$ 1,330,000,000
Revolving Credit Facility | 2012 ABL Revolver
Debt Instrument [Line Items]
Long-term debt outstanding	0
Borrowing capacity	$ 174,900,000

Long-Term Debt - Maturities of

Long-Term Debt - Maturities of Long-term Debt (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Aggregate Future Principal Payments
2024 (remaining nine months ending March 31, 2024)	$ 0
2025	0
2026	0
2027	0
2028	400,000
Thereafter	930,000
Total long-term debt (including current portion)	$ 1,330,000

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Mar. 31, 2023
Senior Notes | 2019 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	$ 400,000	$ 400,000
Senior Notes | 2021 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	600,000	600,000
Term Loans | 2012 Term B-5 Loans | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	330,000	360,000
Fair Value, Measurements, Recurring | Senior Notes | 2019 Senior Notes | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	379,000	383,500
Fair Value, Measurements, Recurring | Senior Notes | 2021 Senior Notes | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	493,500	510,750
Fair Value, Measurements, Recurring | Term Loans | 2012 Term B-5 Loans | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	$ 329,175	$ 359,550

Stockholders' Equity - Narrativ

Stockholders' Equity - Narrative (Details)	3 Months Ended
	Jun. 30, 2023 USD ($) vote $ / shares shares	May 02, 2023 USD ($)	Mar. 31, 2023 $ / shares shares
Stockholders' Equity Note [Abstract]
Common stock, shares authorized (in shares) | shares	250,000,000		250,000,000
Common stock, par value (in USD per share) | $ / shares	$ 0.01		$ 0.01
Preferred stock, shares authorized (in shares) | shares	5,000,000		5,000,000
Preferred stock, par value (in USD per share) | $ / shares	$ 0.01		$ 0.01
Voting rights, number of votes per common share owned | vote	1
Dividends declared on common stock | $	$ 0
Stock repurchase program, authorized amount | $		$ 25,000,000

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Repurchased Shares (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Class of Stock [Line Items]
Total amount repurchased	$ 30,593	$ 43,177
Share Repurchase Program
Class of Stock [Line Items]
Number of shares (in shares)	426,479	677,555
Average price per share (in USD per share)	$ 58.62	$ 55.68
Total amount repurchased	$ 25,000	$ 37,700
Restricted Shares
Class of Stock [Line Items]
Number of shares (in shares)	88,953	99,219
Average price per share (in USD per share)	$ 61.92	$ 54.94
Total amount repurchased	$ 5,500	$ 5,500

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss - Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	$ 1,480,295	$ 1,447,084	$ 1,584,743	$ 1,577,611
Accumulated other comprehensive loss, net of tax
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	(32,210)	(31,564)	$ (29,341)	$ (19,032)
Cumulative translation adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	(32,926)	(32,280)
Unrecognized net gain on pension plans, net of tax of $(214) and $(214), respectively
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	716	716
Other comprehensive loss, cash flow hedge, reclassification tax	$ (214)	$ (214)

Accumulated Other Comprehensi_4

Accumulated Other Comprehensive Loss - Narrative (Details) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2023	Mar. 31, 2023
Stockholders' Equity Note [Abstract]
Reclassification from accumulated other comprehensive loss into earnings	$ 0	$ 0

Earnings Per Share - Computatio

Earnings Per Share - Computation of Basis and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Numerator
Net income	$ 53,276	$ 55,272
Denominator
Denominator for basic earnings per share — weighted average shares outstanding (in shares)	49,767	50,264
Dilutive effect of unvested restricted stock units and options issued to employees and directors (in shares)	429	466
Denominator for diluted earnings per share (in shares)	50,196	50,730
Earnings per Common Share:
Basic earnings per share (in USD per share)	$ 1.07	$ 1.10
Diluted earnings per share (in USD per share)	$ 1.06	$ 1.09

Earnings Per Share - Antidiluti

Earnings Per Share - Antidilutive Securities (Details) - shares shares in Millions	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Outstanding Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	0.4	0.4

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Jun. 30, 2014	Jun. 30, 2023	Jun. 23, 2020	May 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs related to nonvested awards		$ 4.6
Unrecognized compensation costs related to nonvested awards, weighted average period for recognition (years)		2 years 3 months 18 days
Shares available for issuance under the Plan (in shares)		1,900,000
Options exercised, aggregate intrinsic value		$ 3.2
Restricted Stock Units (RSUs) & Performance Stock Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs related to nonvested awards		$ 15.1
Unrecognized compensation costs related to nonvested awards, weighted average period for recognition (years)		2 years 3 months 18 days
Long-term Equity Incentive Plan, 2005
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for grant (in shares)				5,000,000
Number of additional shares authorized (in shares)	1,800,000
Long-term Incentive Plan, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)			2,827,210
Number of new shares for future issuance under 2020 long-term incentive plans (in shares)			2,000,000
Number of unissued shares reserved for 2020 long-term incentive plans (in shares)			827,210

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Based Compensation Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Pre-tax stock-based compensation costs charged against income	$ 4,146	$ 3,857
Income tax benefit recognized on compensation costs	406	537
Total fair value of options and RSUs vested during the period	11,226	10,225
Cash received from the exercise of stock options	7,028	1,489
Tax benefits realized from tax deductions resulting from RSU issuances and stock option exercises	$ 876	$ 2,895

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) - $ / shares	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Shares
Outstanding, beginning of period (in shares)	409,000	440,900
Granted (in shares)	142,800	134,000
Incremental performance shares (in shares)	41,300	42,400
Vested (in shares)	(189,300)	(222,400)
Forfeited (in shares)	(4,200)
Outstanding, end of period (in shares)	399,600	394,900
Vested, end of period (in shares)	108,500	108,500
Weighted Average Grant-Date Fair Value
Outstanding, beginning of period, weighted-average grant-date fair value (in USD per share)	$ 47.17	$ 38.45
Granted, weighted-average grant-date fair value (in USD per share)	61.73	54.47
Vested, weighted-average grant-date fair value (in USD per share)	41.81	32.05
Forfeited, weighted-average grant-date fair value (in USD per share)	54.92
Outstanding, end of period, weighted-average grant-date fair value (in USD per share)	54.18	46.65
Vested, end of period, weighted-average grant-date fair value (in USD per share)	$ 36.54	$ 36.54

Stock-Based Compensation - St_2

Stock-Based Compensation - Stock Option Valuation Assumptions (Details) - Stock Options - USD ($)	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividends	$ 0	$ 0
Granted, weighted-average grant-date fair value (in USD per share)	$ 23.75	$ 20.10
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	30.20%	30.80%
Expected term in years	6 years	6 years
Risk-free rate	3.60%	2.80%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	31.60%	30.90%
Expected term in years	7 years	7 years
Risk-free rate		2.90%

Stock-Based Compensation - St_3

Stock-Based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Shares
Outstanding, beginning of period (in shares)	1,081,000	1,100,900
Granted (in shares)	128,100	197,600
Exercised (in shares)	(172,900)	(39,100)
Forfeited (in shares)	(19,300)
Expired (in shares)	(1,700)
Outstanding, end of period (in shares)	1,015,200	1,259,400
Exercisable, end of period (in shares)	700,100	827,000
Weighted Average Exercise Price
Outstanding, beginning of period, weighted-average exercise price (in USD per share)	$ 43.96	$ 40.62
Granted, weighted-average exercise price (in USD per share)	61.73	54.48
Exercised, weighted-average exercise price (in USD per share)	40.64	38.04
Forfeited, weighted-average exercise price (in USD per share)	54.86
Expired, weighted-average exercise price (in USD per share)	54.47
Outstanding, end of period, weighted-average exercise price (in USD per share)	46.54	42.88
Exercisable, end of period, weighted-average exercise price (in USD per share)	$ 42.70	$ 39.98
Options, Additional Disclosures:
Outstanding, end of period, weighted-average remaining contractual term	6 years 6 months	6 years 10 months 24 days
Exercisable, end of period, weighted-average remaining contractual term	5 years 4 months 24 days	5 years 8 months 12 days
Outstanding, end of period, aggregate intrinsic value	$ 13,369	$ 20,052
Exercisable, end of period, aggregate intrinsic value	$ 11,714	$ 15,567

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Effective income tax rate	22.50%	22%

Concentrations of Risk (Details

Concentrations of Risk (Details) - manufacturer	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Concentration Risk [Line Items]
Number of third-party manufacturers	135	129
Sales | Customer Concentration Risk | Walmart
Concentration Risk [Line Items]
Concentration risk, percentage	20.80%	19.90%
Sales | Customer Concentration Risk | Amazon
Concentration Risk [Line Items]
Concentration risk, percentage	11%
Sales | Supplier Concentration Risk
Concentration Risk [Line Items]
Number of third-party manufacturers with long-term contracts	27	25
Top 5 brands | Sales | Product Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	41%	41.50%
Manufacturers | Sales | Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	74.80%	71%

Business Segments - Information

Business Segments - Information on Operating and Reportable Segments (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Segment Reporting Information, Profit (Loss):
Total revenues	$ 279,309	$ 277,059
Cost of sales	124,636	116,940
Gross profit	154,673	160,119
Advertising and marketing	36,231	39,951
Contribution margin	118,442	120,168
Other operating expenses	33,248	33,154
Operating income	85,194	87,014
North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	246,143	242,518
International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	33,166	34,541
Operating Segments | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	246,143	242,518
Cost of sales	110,076	102,921
Gross profit	136,067	139,597
Advertising and marketing	31,401	35,412
Contribution margin	104,666	104,185
Operating Segments | International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	33,166	34,541
Cost of sales	14,560	14,019
Gross profit	18,606	20,522
Advertising and marketing	4,830	4,539
Contribution margin	13,776	15,983
Intersegment Eliminations | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	$ 1,400	$ 500

Business Segments - Revenue (De

Business Segments - Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	$ 279,309	$ 277,059
Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	28,024	28,250
Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	26,426	27,863
Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	59,911	66,051
Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	57,591	54,094
Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	43,492	43,347
Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	36,016	30,461
Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	24,748	24,145
Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	3,101	2,848
North American OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	246,143	242,518
North American OTC Healthcare | Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	27,182	27,797
North American OTC Healthcare | Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	20,374	21,592
North American OTC Healthcare | Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	54,955	61,184
North American OTC Healthcare | Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	44,681	40,067
North American OTC Healthcare | Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	39,471	38,611
North American OTC Healthcare | Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	34,678	29,455
North American OTC Healthcare | Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	21,726	20,975
North American OTC Healthcare | Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	3,076	2,837
International OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	33,166	34,541
International OTC Healthcare | Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	842	453
International OTC Healthcare | Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	6,052	6,271
International OTC Healthcare | Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	4,956	4,867
International OTC Healthcare | Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	12,910	14,027
International OTC Healthcare | Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	4,021	4,736
International OTC Healthcare | Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	1,338	1,006
International OTC Healthcare | Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	3,022	3,170
International OTC Healthcare | Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	$ 25	$ 11

Subsequent Event (Details)

Subsequent Event (Details) - shares		3 Months Ended
	Aug. 01, 2023	Jun. 30, 2023	Jun. 30, 2022
Subsequent Event [Line Items]
Stock options granted (in shares)		128,100	197,600
Subsequent Event | Director
Subsequent Event [Line Items]
Stock options granted (in shares)	2,295